MiR-145, miR-133a and miR-133b: Tumor-suppressive miRNAs target FSCN1 in esophageal squamous cell carcinoma

International Journal of Cancer

Volumn 127, Issue 12, 2010, Pages 2804-2814

  Kano, Masayuki ^a   Seki, Naohiko ^a   Kikkawa, Naoko ^a   Fujimura, Lisa ^a   Hoshino, Isamu ^a   Akutsu, Yasunori ^a   Chiyomaru, Takeshi ^b   Enokida, Hideki ^b   Nakagawa, Masayuki ^b   Matsubara, Hisahiro ^a  

^a CHIBA UNIVERSITY   (Japan)

^b KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

Esophageal squamous cell carcinoma; FSCN1; MicroRNA; MiR 133a; MiR 133b; MiR 145

Indexed keywords

ACTIN BINDING PROTEIN; FASCIN HOMOLOG 1; MICRORNA; MIR 133A; MIR 133B; MIR 145; NUCLEOTIDE; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ADULT; AGED; ARTICLE; CANCER INHIBITION; CARCINOGENESIS; CELL GROWTH; CELL INVASION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; FSCN1 GENE; GENE; GENE CONTROL; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL;

3' UNTRANSLATED REGIONS; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CARRIER PROTEINS; CELL ADHESION; CELL MOVEMENT; CELL PROLIFERATION; ESOPHAGEAL NEOPLASMS; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; GENES, TUMOR SUPPRESSOR; HUMANS; IMMUNOENZYME TECHNIQUES; LUCIFERASES; MICROFILAMENT PROTEINS; MICRORNAS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 77956181723     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25284     Document Type: Article

References (33)

1. Enzinger PC, Mayer RJ,. Esophageal cancer. N Engl J Med 2003; 349: 2241 -52.
2. Pohl H, Welch HG,. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst 2005; 97: 142 -6.
3. Isono K, Sato H, Nakayama K,. Results of a nationwide study on the three field lymph node dissection of esophageal cancer. Oncology 1991; 48: 411 -20.
4. Pisani P, Parkin DM, Bray F, Felay J,. Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer 1999; 83: 18 -29.
5. Altorki N, Kent M, Ferrara C, Port J,. Three-field lymph node dissection for squamous cell and adenocarcinoma of the esophagus. Ann Surg 2002; 236: 177 -83.
6. Medical Research Council Oesophageal Cancer Working Group. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomized controlled trial. Lancet 2002; 359: 1727 -33.
7. Lin DC, Du XL, Wang MR,. Protein alterations in ESCC and clinical implications: a review. Dis Esophagus 2009; 22: 9 -20.
8. Daigo Y, Nakamura Y,. From cancer genomics to thoracic oncology: discovery of new biomarkers and therapeutic targets for lung and esophageal carcinoma. Gen Thorac Cardiovasc Surg 2008; 56: 43 -53.
9. Bartel DP,. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281 -7.
10. Ambros V,. The functions of animal microRNAs. Nature 2004; 431: 350 -5.
11. He L, Hannon GJ,. MicroRNAs: small RNAs with a big role gene regulation. Nat Rev Genet 2004; 5: 522 -31.
12. Schickel R, Boyerinas B, Park SM, Peter ME,. MicroRNAs: key players in the immune system, differentiation, tumorigenesis and cell death. Oncogene 2008; 27: 5959 -74.
13. Esquela-Kerscher A, Slack FJ,. Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer 2006; 6: 259 -69.
14. Calin GA, Croce CM,. MicroRNA signatures in human cancers. Nat Rev Cancer 2006; 6: 857 -66.
15. Hammond SM,. MicroRNAs as oncogenes. Curr Opin Genet Dev 2006; 16: 4 -9.
16. Zhang B, Pan X, Cobb GP, Anderson TA,. microRNAs as oncogenes and tumor suppressors. Dev Biol 2007; 302: 1 -12.
17. Feber A, Xi L, Luketich JD, Pennathur A, Landreneau RJ, Wu M, Swanson SJ, Godfrey TE, Litle VR,. MicroRNA expression profiles of esophageal cancer. J Thorac Cardiovasc Surg 2008; 135: 255 -60.
18. Guo Y, Chen Z, Zhang L, Zhou F, Shi S, Feng X, Li B, Meng X, Ma X, Luo M, Shao K, Li N, et al. Distinctive microRNA profiles relating to patient survival in esophageal squamous cell carcinoma. Cancer Res 2008; 68: 26 -33.
19. Hiyoshi Y, Kamohara H, Karashima R, Sato N, Imamura Y, Nagai Y, Yoshida N, Toyama E, Hayashi N, Watanabe M, Baba H,. MicroRNA-21 regulates the proliferation and invasion in esophageal squamous cell carcinoma. Clin Cancer Res 2009; 15: 1915 -22.
20. Ichimi K, Enokida H, Okuno Y, Kunimoto R, Chiyomaru T, Kawamoto K, Toki K, Kawakami K, Nishiyama K, Tsujimoto G, Nakagawa M, Seki N,. Identification of novel microRNA targets based on microRNA signatures in bladder cancer. Int J Cancer 2009; 125: 345 -52.
21. Sugimoto T, Seki N, Shimizu S, Kikkawa N, Tsukada J, Shimada H, Sasaki K, Hanazawa T, Okamoto Y, Hata A,. The galanin signaling cascade is a candidate pathway regulating oncogenesis in human squamous cell carcinoma. Genes Chromosomes Cancer 2009; 48: 132 -42.
22. Miller JD, Jain MK, de Gara CJ, Morgan D, Urschel JD,. Effect of surgical experience on results of esophagectomy for esophageal carcinoma. J Surg Oncol 1997; 65: 20 -1.
23. Chan A, Wong A,. Is combined chemotherapy and radiation therapy equally effective as surgical resection in localized esophageal carcinoma? Int J Radiat Oncol Biol Phys 1999; 45: 265 -70.
24. Bandres E, Cubedo E, Agirre X, Malumbres R, Zarate R, Ramirez N, Abajo A, Navarro A, Moreno I, Monzo M, Garcia-Foncillas J,. Identification by real-time PCR of 13 mature microRNAs differentially expressed in colorectal cancer and non-tumoral tissues. Mol Cancer 2006; 5: 29.
25. Schepeler T, Reinert JT, Ostenfeld MS, Christensen LL, Silahtaroglu AN, Dyrskjøt L, Wiuf C, Sørensen FJ, Kruhøffer M, Laurberg S, Kauppinen S, Arntoft TF, et al. Diagnostic and prognostic microRNAs in stage II colon cancer. Cancer Res 2008; 68: 6416 -24.
26. Ozen M, Creighton CJ, Ozdemir M, Ittmann M,. Widespread deregulation of microRNA expression in human prostate cancer. Oncogene 2008; 27: 1788 -93.
27. Cho SC, Chow SC, Au SK,. Restration of tumor suppressor has-miR-145 inhibits cancer cell growth in lung adenocarcinoma patients with epidermal growth factor repector mutation. Eur J Cancer 2009; 45: 2197 -206.
28. Ruan K, Fang X, Ouyang G,. MicroRNAs: novel regulators in the hallmarks of human cancer. Cancer Lett 2009; 285: 116 -26.
29. Adams JC,. Roles of fascin in cell adhesion and motility. Curr Opin Cell Biol 2004; 16: 590 -6.
30. Pelosi G, Pastorino U, Pasini F, Maissoneuve P, Fraggetta F, Iannucci A, Sonzogni A, De Manzoni G, Terzi A, Durante E, Bresaola E, Pezzella F, et al. Independent prognostic value of fascin immunoreactivity in stage I no small cell lung cancer. Br J Cancer 2003; 88: 537 -47.
31. Hashimoto Y, Shimada Y, Kawamura J, Yamasaki S, Imamura M,. The prognostic relevance of fascin expression in human gastric carcinoma. Oncology 2004; 67: 262 -70.
32. Peraud A, Mondal S, Hawkins C, Mastronardi M, Bailey K, Rutka JT,. Expression of fascin, an actin-bundling protein, in astrocytomas of varying grades. Brain Tumor Pathol 2003; 20: 53 -8.
33. Hashimoto Y, Ito T, Okumura T, Tanaka E, Tsunoda S, Higashiyama M, Watanabe G, Imamura M, Shimada Y,. Prognostic significance of fascin overexpression in human esophageal squamous cell carcinoma. Clin Cancer Res 2005; 11: 2597 -605.